Inovalon Insights

by "Inovalon" on 9/12/2016 12:00 PM

Another HEDIS® season has been completed. With 65% of the nation’s clinical and quality outcomes measurement analytics using Inovalon’s platforms, we have analyzed our clients’ results to share some of the best practices and key lessons learned this season to help you prepare for the 2017 HEDIS® submission.

by "Inovalon" on 7/26/2016 3:02 PM

Overly complex quality measures, inadequate access to patient data, and a lack of tools to help collect and assess that data are the reasons many physicians continue to struggle with adoption of value-based care, according to a new study that Inovalon published earlier this month in collaboration with Quest Diagnostics.

by "Quest Diagnostics" on 6/29/2016 3:09 PM

We just announced the findings of a study Quest Diagnostics jointly commissioned with Inovalon entitled, “Finding a Faster Path to Value-Based Care.” We asked physicians and health plan executives how they perceive progress toward value-based care and what challenges may be preventing more rapid adoption.

by "Brad Marks, General Manager, Risk Adjustment Products" on 5/18/2016 10:10 AM

During the second annual EDGE Server submission, participating organizations prepare CMS submissions that are used for interim reinsurance payment calculation and interim risk adjustment summary reporting. The submission process entails cleansing and submitting data, correcting errors, analyzing a myriad of de-identified XML files and filing discrepancy reports. The 15-day extension that was given to insurers in 2015 was not provided in 2016, requiring issuers to meet the May 2 submission deadline.

by "Sandhya Mehta, Zulkarnain Pulungan, Barton T. Jones and Christie Teigland" on 1/5/2016 8:35 AM

The use of second-generation (i.e., atypical) antipsychotic drugs has rapidly expanded in the past decade due to superior tolerability and efficacy compared to conventional (i.e., typical) antipsychotics. From 1996 to 2004 the number of atypical antipsychotic medications prescribed in the elderly increased from 15% to 73%. This upsurge has revealed several safety alerts, the most alarming being the increased risk of mortality with specific cause of death being heart related events and infection (pneumonia in particular). In fact, the FDA issued a black box warning in 2005 indicating increased risk of death in atypical users and extended the warning to typical antipsychotic users in 2008.

Pages